ADP-A2M4N7X19

N/A

Report date: 2022/06/15 15:52:41

Base Information

Drug NameADP-A2M4N7X19
Drug Alias NameADP-A2M4N7X19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen 4 modulatorsInterleukin-7 stimulantsC-C motif chemokine 19 stimulants
TargetsMelanoma-associated antigen 4Interleukin-7C-C motif chemokine 19
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Llc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A